(4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid
• 化学式: C₂₅H₂₂N₄O₈
• 分子量: 506.5
• InChiKey: DLWOTOMWYCRPLK-UVTDQMKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  193
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
  申请人：Myeloid Therapeutics, Inc.

  公开号：EP4025686A2

  公开（公告）日：2022-07-13
• PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC NEPHROPATHY COMPRISING THE ACTIVITY INHIBITOR OF TENC1
  申请人：POSTECH ACADEMY-INDUSTRY FOUNDATION

  公开号：US20160361288A1

  公开（公告）日：2016-12-15

  Provided is a pharmaceutical composition for preventing or treating diabetic nephropathy, comprising a tensin like C1 domain containing phosphatase (TENC1) inhibitor as an active ingredient. A new target for treating diabetic nephropathy is presented by confirming that TENC1 expression is increased in kidney tissue of diabetes or a podocyte cell line to which a high blood glucose environment is given and experimentally proving that nephrin phosphorylation inhibited by the PTPase activity of TENC1 affects the permeability and mTORC1 signaling of the podocytes resulting in inducing podocyte hypertrophy. As the pharmaceutical composition comprising a TENC1 inhibitor as an active ingredient inhibits nephrin dephosphorylation by TENC1, podocytes damaged from an early stage of the diabetic nephropathy may be protected and the structure and filtration function of the podocytes may be maintained, therefore the pharmaceutical composition is expected to be widely used in preventing or treating the diabetic nephropathy from an early stage.
• HOST DEPENDENCY FACTORS AS TARGETS FOR ANTIVIRAL THERAPY
  申请人：Ruprecht-Karls-Universitat Heidelberg

  公开号：US20170128483A1

  公开（公告）日：2017-05-11

  The present invention relates to inhibitor(s) or antagonist(s) of PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use as anti-viral agent(s) as well as for the use in the prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, such as Dengue virus and hepatitis C virus (HCV). The present invention further relates to pharmaceutical compositions or kits comprising said inhibitor(s)/antagonist(s) and methods of preventing and/or treating infection(s) with virus(es) of the Flaviviridae family. The present invention further relates to methods of screening for antiviral agent(s). The present invention relates to PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use in diagnosis, prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, preferably as targets for antiviral treatment or as screening targets.
• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07
• US7927613B2
  申请人：——

  公开号：US7927613B2

  公开（公告）日：2011-04-19